The Lewis lab has had a long interest in the mechanisms of various aspects of diabetic dyslipidemia, including postprandial lipemia, HDL lowering and hypertriglyceridemia, as well as the metabolic effects of free fatty acids on insulin action and secretion. Dr. Lewis and Adeli made the important observation that the intestine overproduces lipoproteins in insulin resistant states, elucidating a number of regulatory mechanisms of intestinal lipid mobilization and lipoprotein secretion. In his current funded work Dr. Lewis is determining, in integrative physiological studies in humans and animal models, the mechanisms of intestinal lipid mobilization and lipoprotein secretion. In addition, Dr. Lewis is the Principal Investigator of Diabetes Action Canada, one of the chronic disease networks funded through the Strategy for Patient-Oriented Research (SPOR) Initiative, and undertakes translational research with active patient engagement.